China Resources Pharmaceutical's subsidiary KPC earned 350 million RMB last year, a decline of 46%
China Resources Pharmaceutical (03320.HK) announced the preliminary performance of its subsidiary KPC (600422.SH) for the fiscal year 2025. Due to a decline in both the sales scale and gross profit margin of the group's products compared to the same period last year, the total operating revenue is expected to be RMB 6.577 billion, a year-on-year decrease of 21.7%. The net profit attributable to shareholders is expected to be RMB 350 million, a decline of 46%
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments